FI19991788A - CD25 sitovia molekyylejä - Google Patents

CD25 sitovia molekyylejä

Info

Publication number
FI19991788A
FI19991788A FI991788A FI19991788A FI19991788A FI 19991788 A FI19991788 A FI 19991788A FI 991788 A FI991788 A FI 991788A FI 19991788 A FI19991788 A FI 19991788A FI 19991788 A FI19991788 A FI 19991788A
Authority
FI
Finland
Prior art keywords
antibodies
binding molecules
paticularly
immunoconjugates
prophylaxis
Prior art date
Application number
FI991788A
Other languages
English (en)
Swedish (sv)
Inventor
Peter Lloyd Amlot
Arne Nalpon Akbar
Guenther Heinrich
Salvatore Gammisuli
Original Assignee
Novartis Ag
Univ London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI19991788(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909005962A external-priority patent/GB9005962D0/en
Priority claimed from GB909019323A external-priority patent/GB9019323D0/en
Application filed by Novartis Ag, Univ London filed Critical Novartis Ag
Publication of FI19991788A publication Critical patent/FI19991788A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
FI991788A 1990-03-16 1999-08-23 CD25 sitovia molekyylejä FI19991788A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909005962A GB9005962D0 (en) 1990-03-16 1990-03-16 Improvements in or relating to organic compounds
GB909019323A GB9019323D0 (en) 1990-09-05 1990-09-05 Improvements relating to immunosuppression

Publications (1)

Publication Number Publication Date
FI19991788A true FI19991788A (fi) 1999-08-23

Family

ID=26296798

Family Applications (3)

Application Number Title Priority Date Filing Date
FI911275A FI103131B (fi) 1990-03-16 1991-03-14 Menetelmä CD25 sitovan molekyylin valmistamiseksi
FI981799A FI104047B1 (fi) 1990-03-16 1998-08-21 DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä
FI991788A FI19991788A (fi) 1990-03-16 1999-08-23 CD25 sitovia molekyylejä

Family Applications Before (2)

Application Number Title Priority Date Filing Date
FI911275A FI103131B (fi) 1990-03-16 1991-03-14 Menetelmä CD25 sitovan molekyylin valmistamiseksi
FI981799A FI104047B1 (fi) 1990-03-16 1998-08-21 DNA-molekyylejä, jotka koodaavat CD25 sitovia molekyylejä

Country Status (23)

Country Link
US (2) US6521230B1 (fi)
EP (1) EP0449769B1 (fi)
JP (1) JP2585475B2 (fi)
AT (1) ATE98655T1 (fi)
AU (1) AU635401B2 (fi)
CA (1) CA2038279C (fi)
CY (1) CY1977A (fi)
DE (2) DE19975033I2 (fi)
DK (1) DK0449769T3 (fi)
ES (1) ES2061216T3 (fi)
FI (3) FI103131B (fi)
HK (1) HK53797A (fi)
HU (2) HUT60768A (fi)
IE (1) IE65062B1 (fi)
IL (1) IL97545A (fi)
LU (1) LU90383I2 (fi)
MY (1) MY106161A (fi)
NL (1) NL990008I2 (fi)
NZ (1) NZ237434A (fi)
PL (1) PL170321B1 (fi)
PT (1) PT97034B (fi)
SA (1) SA92120358B1 (fi)
TW (1) TW213486B (fi)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
JPH07509444A (ja) * 1991-11-26 1995-10-19 アルカーメス・インコーポレーテツド トランスフェリンセレプター特異的抗体−神経薬又は診断薬複合体の製造法
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
AU747260B2 (en) 1997-07-25 2002-05-09 Nichia Chemical Industries, Ltd. Nitride semiconductor device
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
JP3973360B2 (ja) * 1998-07-27 2007-09-12 ノバルティス アクチエンゲゼルシャフト 関節リウマチまたは皮膚疾患の処置に使用するためのｃｄ２５結合分子
WO2000025816A1 (en) * 1998-10-30 2000-05-11 The University Of Miami Treatment of hepatitis c by administration of anti-il-2 receptor monoclonal antibody and an antiviral compound
US6406695B1 (en) 1998-10-30 2002-06-18 University Of Miami Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
FR2793691B1 (fr) * 1999-05-21 2003-10-03 Hippocampe Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
PL363029A1 (en) * 2001-04-06 2004-11-15 University Of Bristol Use of cd25 binding molecules in steroid-resistant patients
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
WO2004045512A2 (en) 2002-11-15 2004-06-03 Genmab A/S Human monoclonal antibodies against cd25
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
EP2270050B1 (en) * 2005-12-30 2013-06-05 Merck Patent GmbH Anti-CD19 antibodies with reduced immunogenicity
CA2718191C (en) 2008-03-13 2018-05-15 Biotest Ag Agent for treating disease
KR20100135257A (ko) 2008-03-13 2010-12-24 바이오테스트 아게 질병 치료제
BRPI0909179A2 (pt) 2008-03-13 2015-08-25 Biotest Ag Composição farmacêutica, e, método de tratamento de uma doença autoimune.
KR102071834B1 (ko) 2009-10-26 2020-01-30 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
KR101819404B1 (ko) 2012-10-12 2018-02-28 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
CN106687141A (zh) 2014-09-10 2017-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其缀合物
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
US9993452B2 (en) * 2014-12-05 2018-06-12 Vireo Systems, Inc. Compositions and methods for treatment of inflammation
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
AU2018253950A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-CD25 antibody-drug conjugate
EP3796942A1 (en) 2018-05-23 2021-03-31 ADC Therapeutics SA Molecular adjuvant
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
CN113924316B (zh) * 2019-06-10 2022-06-21 山东博安生物技术股份有限公司 抗cd25抗体及其应用
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022221669A1 (en) 2021-04-15 2022-10-20 Kyverna Therapeutics, Inc. Methods and compositions for treating disease using targeted foxp3+cd4+ t cells and cellular suicide agents
CN114957473B (zh) * 2022-04-25 2023-05-16 苏州旭光科星抗体生物科技有限公司 一种对可溶性cd25蛋白含量检测的酶联免疫检测试剂盒
WO2024006961A1 (en) 2022-07-01 2024-01-04 Neoleukin Therapeutics, Inc. Neo-2/15 variants and uses thereof for preferentially stimulating t-regulatory cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
ATE108664T1 (de) * 1987-12-02 1994-08-15 Becton Dickinson Co Verfahren zur verhütung von gvhd.
AU631545B2 (en) * 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
DE3815472A1 (de) 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Also Published As

Publication number Publication date
FI981799A (fi) 1998-08-21
FI104047B (fi) 1999-11-15
DE69100768T2 (de) 1994-05-11
FI103131B1 (fi) 1999-04-30
IL97545A0 (en) 1992-06-21
FI103131B (fi) 1999-04-30
MY106161A (en) 1995-03-31
US6383487B1 (en) 2002-05-07
FI911275A0 (fi) 1991-03-14
PT97034A (pt) 1991-10-31
NZ237434A (en) 1992-08-26
ES2061216T3 (es) 1994-12-01
LU90383I2 (fr) 1999-06-07
US6521230B1 (en) 2003-02-18
PL289436A1 (en) 1992-02-24
FI981799A0 (fi) 1998-08-21
JP2585475B2 (ja) 1997-02-26
HK53797A (en) 1997-05-02
TW213486B (fi) 1993-09-21
AU7290991A (en) 1991-09-19
CA2038279C (en) 1999-03-09
NL990008I1 (nl) 1999-06-01
EP0449769B1 (en) 1993-12-15
SA92120358B1 (ar) 2004-01-25
HUT60768A (en) 1992-10-28
CA2038279A1 (en) 1991-09-17
IE65062B1 (en) 1995-10-04
DK0449769T3 (da) 1994-02-21
AU635401B2 (en) 1993-03-18
JPH04316600A (ja) 1992-11-06
CY1977A (en) 1997-09-05
NL990008I2 (nl) 1999-10-01
HU910761D0 (en) 1991-09-30
DE19975033I2 (de) 2007-01-04
DE69100768D1 (de) 1994-01-27
EP0449769A1 (en) 1991-10-02
PL170321B1 (pl) 1996-11-29
PT97034B (pt) 1998-07-31
IL97545A (en) 2000-06-29
FI104047B1 (fi) 1999-11-15
HU211885A9 (en) 1995-12-28
ATE98655T1 (de) 1994-01-15
FI911275A (fi) 1991-09-17
IE910867A1 (en) 1991-09-25

Similar Documents

Publication Publication Date Title
DK0449769T3 (da) CD25-bindende molekyler
DE69429095D1 (de) Humanisierte antikoerper
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
GB2246781A (en) CD3 specific recombinant antibody
RU2005132389A (ru) Гуманизированное анти-cd4 антитело с иммунодепрессивными свойствами
DK0448057T3 (da) Monoklonalt antistof, der reagerer med en hidtil ukendt HLA-determinant på MHC klasse I-molekyler sa mt en fremgangsmåde til aktivereing af lymfocytter
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
ES2112869T3 (es) Anticuerpos monoclonales contra celulas de islotes del pancreas humano.
EP0257778A3 (en) Apolipoprotein b-specific monoclonal antibodies produced by two novel hybridomas
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
KR890016165A (ko) 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도
DK0513565T3 (da) Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse
MY104917A (en) Monoclonal antibodies and methods for diagnosis of phytophora infection
DK0472498T3 (da) Monoklone antistoffer mod Leptosphaeria.
RU92016461A (ru) Культура, линия клеток, моноклональные антитела, способ получения моноклональных антител, способ лечения, способ диагностики